Neuromyelitis optica spectrum disorder (NMOSD) is an antibody-mediated astrocytopathy frequently driven by AQP4-IgG and characterized by severe optic neuritis and longitudinally extensive myelitis. Investigators noted that roughly one-quarter of AQP4-IgG–positive patients carry additional autoimmune disease, most often systemic lupus erythematosus (SLE) or Sjögren’s syndrome, and that the area postrema may be an early but misdiagnosed manifestation presenting as intractable hiccups, nausea, or vomiting. Existing long-term preventive therapies include conventional immunosuppressants and off-label rituximab, but targeted biologics have been approved more recently. Inebilizumab, an anti-CD19 monoclonal antibody, received regulatory approval for AQP4-IgG–seropositive adult NMOSD after randomized data demonstrated substantial attack-risk reduction. The treating team therefore considered inebilizumab for two patients with AQP4-IgG–positive NMOSD complicated by coexisting autoimmune features where conventional management had limitations or produced suboptimal control.
A 29-year-old woman presented with 20 days of recurrent, progressively worse hiccups plus three days of dysphagia; she also had fever and expectoration. MRI identified an abnormal dorsal medullary signal consistent with an area postrema lesion. Cerebrospinal fluid showed elevated microalbumin and immunoglobulins, and serum testing returned positive anti-AQP4 IgG at a titer of 1:100. Rheumatologic testing revealed markedly positive antinuclear antibody and anti-SS-A/anti-Ro-52 serology without overt clinical SLE features; the rheumatology team characterized this as a seropositive autoimmune phenotype and started hydroxychloroquine. The initial neurologic disability measured an Expanded Disability Status Scale (EDSS) score of 4, largely from impaired swallowing.
The patient declined an initial 1,000 mg/day methylprednisolone regimen for side-effect concerns and instead received dexamethasone 10 mg/day for five days without meaningful clinical change. Treatment was escalated to methylprednisolone 500 mg/day plus intravenous immunoglobulin (IVIG, 0.4 g/kg/day for 5 days), after which the EDSS improved to 2. Persistent dysphagia and residual impairment prompted reconsideration of longer-term therapy. Pre-treatment screening identified no contraindications and baseline lymphocyte subset analysis showed elevated CD19+ B cells (19.50% of lymphocytes; absolute count 671.21 cells/μL). The patient received the induction regimen of inebilizumab (300 mg intravenous infusion followed by a second 300 mg dose) on November 22 and December 5, 2024. Clinical improvement was rapid: the EDSS decreased to 0 by the fifth day after the first infusion, and follow-up magnetic resonance imaging demonstrated progressive regression of the dorsal medullary lesion.
The second case involved a patient with a prior NMOSD diagnosis whose disease course had been clinically stable; subsequently the patient developed new generalized myasthenia gravis symptoms and tested positive for acetylcholine receptor (AChR)–IgG. Serial laboratory data provided in the source document show a transition from detectable anti-AQP4 IgG to higher titers at one point, and a marked decline in peripheral CD19+ B-cell counts after treatment. The study team administered inebilizumab in this context and reported clinical benefit for both NMOSD and the overlapping MG phenotype. The article notes that MG co-occurrence poses therapeutic conflicts because corticosteroids can worsen MG and some MG immunosuppressants have limited efficacy against NMOSD attacks.
In Case 1, serial CSF and serum testing documented elevated CSF protein fractions and immune markers at presentation; post-treatment testing showed reductions in CD19+ B-cell percentages and absolute counts. MRI scans obtained at baseline, roughly one month, and at later follow-up revealed progressive lesion regression in the dorsal medulla. In Case 2, tabulated lymphocyte-subset data show CD19+ percentages and absolute counts falling from measurable baseline values to near depletion after therapy; anti-AQP4 and anti-AChR titers were reported serially in the source tables. The authors reported that inebilizumab produced both a cellular depletion signature and parallel clinical improvement in these two patients.
The treating team performed standard pre-treatment screening (hepatitis B, tuberculosis, quantitative immunoglobulins, lymphocyte subsets) and reported no treatment-limiting contraindications. Both patients tolerated inebilizumab without adverse events reported in the source text, and neither patient experienced a documented relapse during the follow-up interval described. In Case 1 the clinical response was rapid, with EDSS dropping to 0 within days of initiation; in Case 2 investigators recorded improvement in MG-related scales and clinical stability of NMOSD during follow-up. The source article did not report detailed safety laboratory trends beyond lymphocyte subsets, nor did it provide formal adverse-event tables in the excerpt provided.
This report describes two individual cases and therefore cannot establish efficacy or safety profiles beyond hypothesis generation. The authors acknowledge the small sample size and the observational case-series design. Specific unanswered questions cited by the study team include optimal timing of inebilizumab initiation during acute NMOSD attacks, its steroid-sparing potential in treatment-naive patients, and the appropriate role of inebilizumab in antibody-overlap phenotypes such as concurrent MG. The source did not provide randomized comparisons, long-term relapse-rate data across a larger cohort, or exhaustive adverse-event surveillance. Prospective, controlled investigations are needed to define the benefit-risk ratio of inebilizumab in NMOSD patients with coexisting autoimmune disease and to guide management where therapeutic conflicts (for example, steroid sensitivity in MG) complicate treatment selection.